Precision Medicine Is The Fastest Growing Segment Fueling The Growth Of Pharmacogenomics Market
Pharmacogenomics Market |
The global Pharmacogenomics
Market is estimated to be valued at US$
33079.39 Mn in 2023 and is expected to exhibit a CAGR of 11.1% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market Overview:
Pharmacogenomics refers to the
use of genome analysis to determine individual patient's genetic
predispositions to specific drugs and drug doses. It helps optimize drug
therapies for patients based on their DNA. This avoids adverse effects and
improves treatment effectiveness.
Market key trends:
One of the key trends in the
pharmacogenomics market is the increasing adoption of precision medicine
approaches. Precision medicine is a medical model using genetic, biomarker,
lifestyle and environmental information to classify individuals into specific
diseases and treatment protocols. In pharmacogenomics, precision medicine helps
doctors to select specific drugs and doses based on a person's genes. For
instance, patients who are CYP2C19 poor metabolizers may experience adverse
drug reactions when prescribed clopidogrel. Precision pharmacogenomics enables
optimization of treatment regimen based on individual patient's genetic
profile. This significantly improves treatment outcomes and safety.
Segment Analysis
The pharmacogenomics market is
segmented by technology into microarray, polymerase chain reaction (PCR),
sequencing, and mass spectrometry. Among these, the sequencing segment holds
the largest market share as it helps in whole-genome sequencing and has become
a widely adopted technique. Moreover, next generation sequencing has enabled
high-throughput analysis of genomic data, making it an advanced and dominant
technology in the pharmacogenomics market.
Key Takeaways
The Global
Pharmacogenomics Market Size is expected to witness high
growth, exhibiting a CAGR of 11.1%
over the forecast period, due to increasing adoption of personalized medicine
and companion diagnostics.
Regional analysis
North America presently dominates
the global pharmacogenomics market and is predicted to continue its dominance
over the forecast period. This is attributed to the increasing adoption of
personalized medicine, growing awareness regarding pharmacogenomics, and rising
government funding for research in the US and Canada. Asia Pacific is expected
to grow at the fastest rate due to rising healthcare expenditure, increasing
research & development investments, and emergence of several local players
in the region.
Key players
Key players operating in the
pharmacogenomics market are Admera Health, Abbott Laboratories, Agilent
Technologies, Novartis AG, Dynamic DNA Laboratories, Empire Genomics, LLC., F.
Hoffmann-La Roche Ltd., Illumina, Inc., OneOme, LLC, Myriad Genetics Inc., OPKO
Health, Inc. (GeneDx.), Thermo Fisher Scientific, Inc., and AltheaDx. Companies
are focusing on new product launches and enhancements, investments in R&D,
and geographical expansions to strengthen their position in the market. For
instance, in April 2022, Dynamic DNA Laboratories launched a pharmacogenomics
sequencing service to enable precision medication decisions.
Get More Insights Here
https://www.newsstatix.com/pharmacogenomics-market-size-share-growth-outlook-2023/
Comments
Post a Comment